Breaking News, Collaborations & Alliances

Agilis, Intrexon in Rare Disease Pact

To advance DNA-based therapeutics for Friedreich's ataxia

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Agilis Biotherapeutics and Intrexon Corp. have entered an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich’s ataxia (FRDA), a rare genetic neurodegenerative disease. The companies will explore DNA-based therapeutics to directly target underlying disease mechanisms using tightly-controlled gene therapies for patients with rare inherited diseases such as FRDA.   Agilis will employ its Intrexon’s UltraVector platform and RheoSwitch Therapeutic Syste...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters